Impact of Mid-Urethral Sling Surgery on Sexual Function in Women with Stress Urinary Incontinence: A Meta-Analysis of Randomized Controlled Trials

MUS surgery improved PISQ-12 scores by 4.49 points at 6 months, but the gains largely reversed by 12 months and didn't recover

Journal: The Journal of Sexual Medicine | Published: 2026-04-09 | Type: Meta-Analysis, Systematic Review | PMID: 41967068 Authors: Soares et al. — Indiana University Department of Urology (Burns, Bernie), with co-authors from Brazilian institutions and University of Rochester Funding/COI: Not listed for either

Summary

Mid-urethral slings (MUS) are the standard surgical fix for stress urinary incontinence, and the logic is intuitive: if leaking during sex kills the mood, stopping the leak should help. This meta-analysis of 11 RCTs and 2,909 women confirms a real short-term gain on the PISQ-12 sexual function scale at 6 months — but that gain shrinks substantially by 12 months and becomes statistically indistinguishable from baseline by 24 and 36 months. The headline finding is not that surgery helps; it's that the help doesn't last.

Claims

• At 6 months post-MUS, pooled PISQ-12 scores improved by a mean of 4.49 points from baseline (95% CI 3.51–5.46) across 11 RCTs
• By 12 months, scores had declined 2.68 points relative to the 6-month peak (95% CI 0.67–4.70) — partially erasing the initial gain
• At 24 months, the change from 12 months was -0.52 points (95% CI -2.71 to 1.68; P=0.31) — not statistically significant
• At 36 months, change was +0.11 points (95% CI -1.95 to 2.17; P=0.53) — also not significant
• Sling type (transobturator 60.1%, single-incision 22.6%, retropubic 17.4%) did not significantly affect outcomes except at 12 months, where the transobturator group showed a greater decline than the other types
• No significant differences between sling types at 6, 24, or 36 months

Study Quality

Methodologically, this is about as good as a meta-analysis of this topic can currently be. Restricting inclusion to RCTs, using a standardized validated instrument (PISQ-12), applying a random-effects model, and conducting pre-specified subgroup analyses by sling type are all correct calls. The 11-study, 2,909-patient pool is reasonable for a surgical literature that tends toward small, short trials.

That said, a single-arm meta-analysis of single means — which is what this is — cannot establish causation in the way a controlled comparison can. There's no sham-surgery control. The 4.49-point improvement at 6 months could partly reflect relief from leaking during intercourse (the actual target of surgery) rather than any sling-specific sexual effect. The authors use Review Manager v5.4 and R v4.3.3 with appropriate random-effects modeling; no major statistical complaints.

Red Flags

• No control group. Single-arm design means natural disease course, regression to the mean, and placebo effects cannot be separated from surgical effects
• Funding and COI not reported. MUS are a high-revenue surgical market; undisclosed industry ties are a genuine concern here
• Heterogeneity not quantified in the abstract. Pooling across three mechanistically distinct sling types at differing follow-up intervals likely generates substantial I², which the abstract does not report
• PISQ-12 MCID is approximately 4–5 points on a 0–48 scale; the 6-month gain of 4.49 just clears that threshold — this is clinically marginal, not a robust improvement
• Attrition across follow-up. Studies contributing to 36-month data are a subset of those contributing to 6-month data; comparing pooled means across different study subsets at different time points is not a true within-patient trajectory
• "Patient education" framing in the conclusion edges toward clinical advice — the scope here is describing what the data show, not counseling patients on expectations

Strengths

• RCT-only inclusion is the right filter for a surgical intervention meta-analysis
• Consistent use of a single validated instrument (PISQ-12) across all time points enables meaningful pooling
• Subgroup analysis by sling type adds clinically relevant granularity
• Reasonably large pooled N (2,909) for a surgical sexual function study
• Pre-registration and multi-database search (PubMed, Cochrane, Embase) follow current systematic review standards

Verdict

This meta-analysis does one thing well: it documents that the sexual function improvement from MUS surgery is real at 6 months but does not persist. That's a clinically meaningful finding — not because it indicts the surgery (stress urinary incontinence itself harms sexual function, and fixing it has real value), but because it challenges the assumption that surgical cure of incontinence automatically sustains sexual benefit long-term. The methodological ceiling here is the single-arm design: you can't know how much of the 6-month gain is surgical effect versus relief from a distressing symptom versus placebo versus natural variation. Well-designed for what it is, honest about its limits, worth reading if you care about pelvic floor surgery outcomes — but the absence of funding disclosure on a paper in a commercially active surgical space is a routine annoyance that reviewers and journals should stop tolerating.